Hereditary Breast Cancer: The Era of New Susceptibility Genes

Breast cancer is the most common malignancy among females. 5%–10% of breast cancer cases are hereditary and are caused by pathogenic mutations in the considered reference BRCA1 and BRCA2 genes. As sequencing technologies evolve, more susceptible genes have been discovered and BRCA1 and BRCA2 predisposition seems to be only a part of the story. These new findings include rare germline mutations in other high penetrant genes, the most important of which include TP53 mutations in Li-Fraumeni syndrome, STK11 mutations in Peutz-Jeghers syndrome, and PTEN mutations in Cowden syndrome. Furthermore, more frequent, but less penetrant, mutations have been identified in families with breast cancer clustering, in moderate or low penetrant genes, such as CHEK2, ATM, PALB2, and BRIP1. This paper will summarize all current data on new findings in breast cancer susceptibility genes.

[1]  R. Eeles,et al.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.

[2]  P. Radice,et al.  Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families , 2012, Familial Cancer.

[3]  A. Spigelman,et al.  Cancer and the Peutz-Jeghers syndrome. , 1989, Gut.

[4]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[5]  F. Saulnier,et al.  Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case–control study , 2005, Critical care.

[6]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[7]  E. Seemanová,et al.  Cancer risk of heterozygotes with the NBN founder mutation. , 2007, Journal of the National Cancer Institute.

[8]  A. Whittemore,et al.  Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study , 2010, Breast Cancer Research.

[9]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[10]  Franca Fraternali,et al.  Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.

[11]  A. W. van der Vaart,et al.  CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women , 2011, Journal of Medical Genetics.

[12]  S. Gruber,et al.  Relative frequency and morphology of cancers in STK11 mutation carriers. , 2004, Gastroenterology.

[13]  E. Fishman,et al.  Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  R. Hruban,et al.  Advances in counselling and surveillance of patients at risk for pancreatic cancer , 2007, Gut.

[16]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[17]  F. Couch,et al.  Rare variants in XRCC2 as breast cancer susceptibility alleles , 2012, Journal of Medical Genetics.

[18]  S. Gruber,et al.  Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome , 2006, Clinical Cancer Research.

[19]  David J. Chen,et al.  Evidence for Simultaneous Protein Interactions between Human Rad51 Paralogs* , 2000, The Journal of Biological Chemistry.

[20]  D. Lane,et al.  Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. , 1994, British Journal of Cancer.

[21]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[22]  W. Foulkes,et al.  Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families , 2012, British Journal of Cancer.

[23]  M. Dąbrowska,et al.  A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.

[24]  Arto Mannermaa,et al.  RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. , 2005, Carcinogenesis.

[25]  Leif E. Peterson,et al.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Daniel J. Park,et al.  Rare mutations in XRCC2 increase the risk of breast cancer. , 2012, American journal of human genetics.

[27]  B. Graveley Sorting out the complexity of SR protein functions. , 2000, RNA.

[28]  P. Møller,et al.  Peutz–Jeghers syndrome: a systematic review and recommendations for management , 2010, Gut.

[29]  F. Arwert,et al.  The Cowden syndrome: a clinical and genetic study in 21 patients , 1986, Clinical genetics.

[30]  Y. Labrie,et al.  Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer , 2009, BMC Cancer.

[31]  M. Polymeropoulos,et al.  Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. , 1998, Cancer research.

[32]  W. Foulkes BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis , 2005, Familial Cancer.

[33]  T. Dörk,et al.  Nijmegen Breakage Syndrome mutations and risk of breast cancer , 2008, International journal of cancer.

[34]  W. Heyer,et al.  Regulation of homologous recombination in eukaryotes. , 2010, Annual review of genetics.

[35]  R. Winqvist,et al.  Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility , 2003, Journal of medical genetics.

[36]  D. Jong,et al.  Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance , 2012, Familial Cancer.

[37]  N. Camp,et al.  A role for XRCC2 gene polymorphisms in breast cancer risk and survival , 2011, Journal of Medical Genetics.

[38]  J. Struewing,et al.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation , 1998, The Lancet.

[39]  A. Risch,et al.  Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations , 2013, Clinical genetics.

[40]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[42]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[43]  F. Graziano,et al.  The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  B. Fernandez,et al.  Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.

[45]  N. Aaronson,et al.  Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits , 2010, Familial Cancer.

[46]  W. Foulkes,et al.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.

[47]  J. Petrini,et al.  Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. , 2009, DNA repair.

[48]  J. Benítez,et al.  Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. , 2012, Human molecular genetics.

[49]  D. Allain Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. , 2008, The Journal of molecular diagnostics : JMD.

[50]  M. Swift,et al.  Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. , 1986, Journal of the National Cancer Institute.

[51]  Rochelle L. Garcia,et al.  Loss of function germline mutations in RAD51D in women with ovarian carcinoma. , 2012, Gynecologic oncology.

[52]  J. Heverhagen,et al.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer , 2009, Gut.

[53]  C. Bonaïti‐pellié,et al.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals , 2000, British Journal of Cancer.

[54]  R. Gatti,et al.  Ataxia-telangiectasia, an evolving phenotype. , 2004, DNA repair.

[55]  A. Krainer,et al.  Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.

[56]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[57]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[58]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[59]  E. Swisher,et al.  Hereditary ovarian cancer: beyond the usual suspects. , 2012, Gynecologic oncology.

[60]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[61]  Cancer predisposing BARD1 mutations in breast–ovarian cancer families , 2011, Breast Cancer Research and Treatment.

[62]  E. Seemanová An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. , 1990, Mutation research.

[63]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[64]  S. Singh,et al.  Gall-bladder polyps in Peutz-Jeghers syndrome. , 1980, Postgraduate medical journal.

[65]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[66]  D. Yannoukakos,et al.  Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. , 2007, European journal of cancer.

[67]  C. Begg,et al.  Rare germline mutations in PALB2 and breast cancer risk: A population‐based study , 2012, Human mutation.

[68]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[69]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[70]  Katri Pylkäs,et al.  Breast Cancer–Associated Abraxas Mutation Disrupts Nuclear Localization and DNA Damage Response Functions , 2012, Science Translational Medicine.

[71]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  A. Jakubowska,et al.  A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland , 2007, Breast Cancer Research and Treatment.

[73]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[74]  J. Schleutker,et al.  RAD51C is a susceptibility gene for ovarian cancer. , 2011, Human molecular genetics.

[75]  Deborah Hughes,et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.

[76]  C Caldas,et al.  Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.

[77]  C. Eng Role of PTEN, a Lipid Phosphatase Upstream Effector of Protein Kinase B, in Epithelial Thyroid Carcinogenesis , 2002, Annals of the New York Academy of Sciences.

[78]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[79]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.

[80]  K. Thornton,et al.  Current Guidelines and Best Practice Evidence for Intensified/Enhanced Breast Cancer Screening in Women with BRCA Mutations , 2009 .

[81]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[82]  N. Rahman,et al.  ATM and breast cancer susceptibility , 2006, Oncogene.

[83]  H. Nevanlinna,et al.  Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer‐predisposing gene , 2008, Molecular oncology.

[84]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[85]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[86]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[87]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[88]  M. Thun,et al.  Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 , 2009, Nature Genetics.

[89]  D. Wattendorf,et al.  Translational advances regarding hereditary breast cancer syndromes , 2012, Journal of surgical oncology.

[90]  B. Vogelstein,et al.  BRCA1 and BRCA2 Genes , 2003 .

[91]  S. Elledge,et al.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. , 2000, Genes & development.

[92]  Susan L Neuhausen,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A Jakubowska,et al.  Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations , 2008, Journal of Medical Genetics.

[94]  M. King,et al.  Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[95]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[96]  Ron Brown,et al.  The Henry Ford production system: LEAN process redesign improves service in the molecular diagnostic laboratory: a paper from the 2008 William Beaumont hospital symposium on molecular pathology. , 2009, The Journal of molecular diagnostics : JMD.

[97]  B. Blencowe Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. , 2000, Trends in biochemical sciences.

[98]  Robert T Abraham,et al.  PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. , 2004, DNA repair.

[99]  H. Höfler,et al.  Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. , 1999, The American journal of pathology.

[100]  H. Olsson Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[101]  C. Eng Will the real Cowden syndrome please stand up: revised diagnostic criteria , 2000, Journal of medical genetics.

[102]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[103]  D. Easton,et al.  High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. , 1996, Cancer research.

[104]  F. Fostira,et al.  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study , 2012, Breast Cancer Research and Treatment.

[105]  S. Gruber,et al.  Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. , 2007, JAMA.

[106]  R F Phipps,et al.  Familial breast cancer. , 1988, Postgraduate medical journal.

[107]  M. King,et al.  Response to DNA damage of CHEK2 missense mutations in familial breast cancer. , 2012, Human molecular genetics.

[108]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[109]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[110]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[111]  P. Mullis,et al.  An exon splice enhancer mutation causes autosomal dominant GH deficiency. , 2002, The Journal of clinical endocrinology and metabolism.

[112]  C. Lázaro,et al.  Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes , 2012, Breast Cancer Research and Treatment.

[113]  Steven P Gygi,et al.  Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response , 2007, Science.

[114]  E. Sensi,et al.  Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations , 2002, Genes, chromosomes & cancer.

[115]  A. Spurdle,et al.  Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts , 2010, BMC Medical Genetics.

[116]  J. Thacker,et al.  The importance of XRCC2 in RAD51-related DNA damage repair. , 2010, DNA repair.

[117]  L. Aaltonen,et al.  A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer , 2012, Journal of Medical Genetics.

[118]  A. Børresen-Dale,et al.  Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study , 2008, British Journal of Cancer.

[119]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[120]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[121]  A J Krush,et al.  Increased risk of cancer in the Peutz-Jeghers syndrome. , 1987, The New England journal of medicine.

[122]  Victoria L. Cafourek,et al.  Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. , 2011, Journal of the National Cancer Institute.

[123]  D. Yannoukakos,et al.  Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients , 2008, Breast Cancer Research and Treatment.

[124]  D. Huntsman,et al.  E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. , 2003, Human molecular genetics.

[125]  A. Gylfason,et al.  Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.

[126]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[127]  M. King,et al.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.

[128]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[129]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  Olufunmilayo I Olopade,et al.  BRCA2 T2722R is a deleterious allele that causes exon skipping. , 2002, American journal of human genetics.

[131]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[132]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[133]  E. Kuipers,et al.  High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations , 2010, The American Journal of Gastroenterology.